Takeda Selected by the FTSE4Good Developed Index for the 14th Consecutive Year
Takeda Selected by the FTSE4Good Developed Index for the 14th Consecutive Year
Osaka, Japan, July 11, 2018 --- Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502) announced today that it has been selected for the 14th consecutive year in the FTSE4Good Developed Index (formerly FTSE4 Good Global Index) of the FTSE4Good Index Series, one of the world’s premier indices for Socially Responsible Investment (SRI)*.
Created by the global index provider FTSE Russell**, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices. The FTSE4Good indices are used by a wide variety of market participants when creating or assessing sustainable investment products. Takeda was highly recognized for its rating on "Climate Change", "Water Use", and "Corporate Governance" based on its continued efforts towards strengthening corporate social responsibility (CSR) activities as well as information disclosure.
As a pharmaceutical company committed to improving people’s lives, Takeda will continue fulfilling its social responsibility as a global pharmaceutical company to strive towards Better Health and a Brighter Future for people worldwide through leading innovation in medicine.
In addition to the FTSE4Good Developed Index, Takeda is selected in other benchmark SRI indices as below:
|
Name of Index/Investment Universe***/Ratings |
Company/Organization |
Country |
Number of selection |
|
Dow Jones Sustainability Asia Pacific Index |
S&P Dow Jones Indices |
US |
8th consecutive year |
|
Ethibel EXCELLENCE Investment Register |
Forum Ethibel |
BEL |
three times |
|
Prime Status |
Oekom |
GER |
first time |
|
Global 100 Most Sustainable Corporations in the World Index |
Corporate Knights |
CND |
3rd consecutive year |
* SRI evaluates investments in companies not only in terms of financial performance, but also with an emphasis on corporate social responsibility performance from social, ethical, environmental, and other perspectives.
** An independent company owned by the London Stock Exchange, FTSE Russell provides global index and analytical solutions.
*** A specific group or category of investments that share certain characteristics.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care all over the world.
For more information, visit https://www.takeda.com/newsroom/
About Takeda’s Sustainable Value Report
Takeda’s annual Sustainable Value Report showcases how the company is addressing the world’s biggest challenges to sustainable development over the long-term. Data included are primarily non-financial, focusing on Takeda’s diverse CSR commitments, as well as how CSR priorities are inextricably linked to the company’s DNA. Takeda leverages such benchmarks as the international integrated reporting framework of the International Integrated Reporting Council (IIRC), United Nations Global Compact’s advanced level assessment criteria, and Global Reporting Initiative (GRI) Standards to create a comprehensive report that incorporates high standards of transparency and disclosure, targeting a broad range of stakeholders.
For more information, visit https://www.takeda.com/corporate-responsibility/Sustainable-Value-Report/.
Media Contacts:
Kazumi Kobayashi
[email protected]
+81 (0) 3-3278-2095